Status:
COMPLETED
Study Evaluating Single Doses of BLI-489 in Healthy Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy Subjects
Eligibility:
All Genders
20-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety, and tolerability of single doses of BLI-489 administered intravenously in healthy subjects, and also how the drug is absorbed and eliminated.
Eligibility Criteria
Inclusion
- Men or women of nonchildbearing potential, 18 to 50 years of age inclusive at screening.
- Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight greater than or equal to 50 kg.
- Healthy as determined by the investigator on the basis of the screening evaluations.
- Nonsmoker of smoker of fewer than 10 cigarettes per day as determined by history.
Exclusion
- Presence of history of any disorder that may prevent the successful completion of the study.
- History of drug abuse within 1 year.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00820404
Start Date
January 1 2009
End Date
April 1 2009
Last Update
July 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Philadelphia, Pennsylvania, United States, 19148